ERBB2 and breast carcinoma: Trastuzumab (Herceptin) is the first anti-HER-2 antibody to be used for the treatment of breast cancer expressing high levels of HER-2 (Press et al, 2002; Ross et al, 2003) and in their adjuvant setting.